Financials data is unavailable for this security.
View more
Year on year Nxera Pharma Co Ltd 's revenues fell -18.00% from 15.57bn to 12.77bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 382.00m to a loss of 7.19bn.
| Gross margin | 75.27% |
|---|---|
| Net profit margin | -12.68% |
| Operating margin | -14.96% |
| Return on assets | -2.46% |
|---|---|
| Return on equity | -5.90% |
| Return on investment | -2.76% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Nxera Pharma Co Ltd fell by 17.49bn. Cash Flow from Financing totalled 48.33bn or 378.58% of revenues. In addition the company used 5.27bn for operations while cash used for investing totalled 63.79bn.
| Cash flow per share | 2.86 |
|---|---|
| Price/Cash flow per share | 405.63 |
| Book value per share | 753.72 |
|---|---|
| Tangible book value per share | -100.71 |
More ▼
Balance sheet in JPYView more
| Current ratio | 4.01 |
|---|---|
| Quick ratio | 3.90 |
| Total debt/total equity | 1.02 |
|---|---|
| Total debt/total capital | 0.5060 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items dropped -1,984.67%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 2.76 |
